Continuous Flow Chemistry for API Manufacturing: Powerful Technology, but Not a Universal Solution

Continuous flow chemistry is often presented as part of the future of pharmaceutical manufacturing. There is good reason for the enthusiasm. For the right chemical process, continuous flow can reduce equipment size, improve heat and mass transfer, strengthen process control, improve safety and dramatically reduce the physical footprint required to manufacture active pharmaceutical ingredients (APIs).

But there is an important qualification.

Flow chemistry is not automatically cheaper, greener or better than conventional batch manufacturing. Its economic advantage depends heavily on the chemistry itself, particularly reaction kinetics, concentrations, solubility, downstream purification and the amount of solvent that must be handled.

In Maravion’s view, the question should therefore not be: “Can this API be manufactured using continuous flow chemistry?”

The better question is: “Which parts of this API manufacturing process should be continuous, which should remain batch, and which configuration produces the best techno-economic outcome?”

That distinction matters.

1              Why continuous flow chemistry is attractive for API manufacturing

Traditional active pharmaceutical ingredient manufacturing typically relies on batch processing. Reactions take place in relatively large vessels, followed by operations such as extraction, separation, crystallisation, filtration, drying and intermediate storage.

Continuous flow chemistry changes this manufacturing philosophy. Reactants are continuously introduced into comparatively small reactors, with reaction conditions tightly controlled as material passes through the system.

One of its most compelling advantages is process intensification.

A conventional API manufacturing facility may require substantial reactor volumes, associated utilities and supporting infrastructure. A continuous flow reactor can achieve significant throughput from much smaller equipment because material does not need to remain in a large vessel for an entire batch cycle.

Published pharmaceutical-industry reviews identify smaller equipment footprint, improved reaction control, enhanced safety and the ability to undertake chemistry that can be difficult in conventional batch systems among the important advantages of continuous flow processing. 

Maravion's previous assessments of API manufacturing opportunities have similarly identified reduced manufacturing footprint as one of the potentially significant economic advantages of continuous processing. 

For regions seeking to establish new API manufacturing capacity, this is particularly relevant. A smaller process plant can potentially translate into lower capital requirements for process equipment and associated buildings and infrastructure.

However, the reactor is only one part of an API manufacturing plant.

And this is where the economics become more complicated.

2              Flow chemistry works particularly well at high concentrations

The economic case for continuous flow becomes particularly interesting when reactions can operate neat, where appropriate, or using highly concentrated homogeneous solutions.

If reactants and intermediates remain soluble throughout the relevant reaction stages, relatively large quantities of product can pass through comparatively small reactor volumes.

This is where the small-footprint argument for flow chemistry becomes particularly powerful.

High concentrations mean less solvent needs to be pumped, heated, cooled, separated and recovered for every kilogram of API produced. Equipment can remain comparatively compact and the process-intensification advantages of continuous flow can translate into meaningful reductions in plant size.

The important word, however, is homogeneous.

Once poor solubility enters the process, the economics can change substantially.

3              The solvent problem can undermine the business case

A reaction can work extremely well in a laboratory flow reactor and still make little economic sense at commercial scale.

Consider what happens when an intermediate or product has limited solubility.

Solids can precipitate and cause fouling or blockage in flow reactors. One apparently straightforward laboratory solution is to add more solvent until everything remains dissolved.

Chemically, the problem may have been solved.

Economically, it may have created a much bigger one.

This issue emerged clearly in API process scale-up work previously assessed by Maravion. Limited solubility resulted in plugging of small flow reactors. Increasing solvent volumes maintained solubility at laboratory scale, but the resulting solvent ratios meant that commercial processing equipment would have to become substantially larger. More importantly, the cost and infrastructure associated with solvent recovery significantly weakened the economic case for continuous processing. 

This is not a minor consideration. Solvents frequently dominate the material consumption of pharmaceutical chemical processes. A widely cited pharmaceutical-industry analysis found that solvents can account for 80 to 90% of mass utilisation in typical pharmaceutical and fine-chemical batch operations. 

If a continuous process requires extensive dilution simply to keep intermediates and products in solution, much of the apparent process intensification can disappear.

4              The reactor may be small while the solvent plant becomes very large

This leads to an important principle when evaluating continuous flow API manufacturing:

Do not evaluate the size and cost of the flow reactor in isolation.

A flow reactor may occupy remarkably little space. But if every kilogram of API requires tens or hundreds of kilograms of solvent to maintain a homogeneous solution, the overall manufacturing facility may still require substantial infrastructure.

That can include solvent storage, distillation and recovery systems, condensers, tanks, pumps, heat exchangers, utilities, waste treatment and appropriate environmental and safety systems.

Solvent recovery itself also consumes energy and operating resources.

Recovered solvents can certainly be reused within pharmaceutical manufacturing, provided appropriate controls and specifications are maintained, and this is recognised within GMP guidance for API manufacture. But the fact that solvent can be recovered does not mean that recovery is economically free.

This is why solvent balance should be part of the techno-economic analysis from the beginning.

If flow chemistry reduces the reactor footprint but simultaneously creates a large solvent-recovery operation, the supposed capital and operating cost advantage needs to be reconsidered.

Research comparing continuous and batch pharmaceutical manufacturing reaches a similar conclusion. Continuous processing can improve sustainability metrics, but increased solvent consumption can also make the environmental performance of a flow process worse than its batch equivalent. 

The same principle applies economically.

5              Sometimes batch manufacturing is simply the better technology

There is nothing inherently outdated about batch manufacturing.

Large batch reactors are extremely effective pieces of chemical-processing equipment. They can accommodate heterogeneous systems, slurries, precipitation and solids more readily than many small-channel continuous reactors.

For reactions involving poorly soluble intermediates or products, a batch reactor may therefore offer a simpler and more economical solution than continually adding solvent simply to make the chemistry compatible with a flow system.

The important comparison is not technological sophistication. It is cost per kilogram of API meeting the required quality specification.

If maintaining a continuous homogeneous phase requires so much solvent that solvent recovery, utilities and downstream equipment dominate the economics, reverting that operation to batch processing may be the more rational engineering decision.

6              Hybrid flow-batch manufacturing may offer the best solution

Fortunately, API manufacturers do not have to choose between an entirely continuous plant and an entirely batch plant.

A hybrid manufacturing process can combine the strengths of both.

Some reaction steps may be particularly well suited to continuous flow because they involve rapid reactions, hazardous chemistry, demanding temperature control or highly concentrated homogeneous solutions.

Other steps may be better suited to batch processing because they involve precipitation, crystallisation, solids handling, long reaction times or intermediate isolation.

This is not merely a theoretical approach. International regulatory guidance explicitly recognises drug-substance manufacturing systems containing both continuous and batch operations. The ICH Q13 example published by the FDA illustrates a process in which continuous reaction and separation operations coexist with batch intermediate and final processing operations. 

That is an important point for API process design.

The objective should not be maximum continuous processing.

It should be optimum processing.

7              Follow the economics, not the technology

A credible assessment of continuous flow chemistry therefore requires the entire process to be evaluated rather than focusing only on reaction yield or reactor performance.

For each stage of an API synthesis, the analysis should consider reaction concentration, solubility, residence time, yield, selectivity, impurity formation, solvent consumption, solvent recovery, energy requirements, downstream isolation, purification, equipment requirements and process scale-up.

These technical parameters then need to feed into the financial model.

The resulting techno-economic analysis can compare alternative configurations such as a conventional batch process, a fully continuous process and one or more hybrid flow-batch configurations.

Only then can the real effect on capital expenditure, operating expenditure and cost of goods be understood.

This is particularly important for generic APIs, where manufacturers may be competing against established international producers operating highly optimised and, in some cases, substantially depreciated manufacturing assets. Maravion's previous pharmaceutical manufacturing assessments have demonstrated how strongly input costs, intermediates, process configuration and manufacturing economics can influence the viability of new API capacity. 

A technically elegant process that cannot achieve a competitive manufacturing cost is not a competitive manufacturing technology.

8              Flow chemistry has its place, and it can be a very important one

Continuous flow chemistry should neither be dismissed nor treated as the inevitable replacement for batch API manufacturing.

For the right chemistry, its advantages can be substantial.

When reactions can operate neat or at high concentrations, intermediates remain soluble, residence times are appropriate and downstream operations integrate efficiently, continuous flow can deliver genuine process intensification. Smaller reactors can translate into a significantly smaller manufacturing footprint, potentially reducing capital requirements while improving process control and safety.

But poor solubility can fundamentally alter that equation.

If maintaining homogeneous solutions requires excessive dilution, solvent volumes increase. The equipment needed to handle and recover those solvents grows accordingly. Energy consumption and operating costs increase. Eventually, the solvent-recovery plant can overwhelm the economic advantage created by the small flow reactor.

At that point, batch processing may make more sense.

And often the optimum solution lies somewhere between the two.

The future of API manufacturing may therefore be less about choosing continuous flow chemistry over batch manufacturing and more about intelligently combining the two. Each reaction and unit operation should use the technology that provides the best technical, regulatory and economic outcome.

That is ultimately the role of techno-economic analysis: not to validate a preferred technology, but to determine which manufacturing configuration actually creates value.

9              How Maravion can assist

Maravion supports pharmaceutical manufacturers, technology developers, investors and public-sector organisations in evaluating API manufacturing opportunities across the complete pharmaceutical value chain.

This includes pharmaceutical industry and API market assessments, process scale-up evaluations, process design reviews, assessment of continuous flow and batch manufacturing strategies, raw material and pharmaceutical intermediate analysis, capital and operating cost estimation, cost-of-goods modelling, financial modelling, risk analysis and techno-economic feasibility studies.

For continuous flow chemistry in particular, Maravion can evaluate whether the theoretical advantages of a smaller manufacturing footprint survive when the complete commercial process is considered, including solvent consumption and recovery, downstream purification, utilities, cGMP infrastructure and commercial-scale equipment.

The question is therefore not whether continuous flow chemistry is a good technology.

It is whether it is the right technology, for the right reaction, at the right scale, at a competitive cost.

For API manufacturing, that is the distinction that ultimately matters.

Continuous Flow Chemistry for API Manufacturing: Powerful Technology, but Not a Universal Solution